Company Description
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Pratik Shah |
Contact Details
Address: 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 United States | |
| Phone | 858 293 4900 |
| Website | designtx.com |
Stock Details
| Ticker Symbol | DSGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001807120 |
| CUSIP Number | 25056L103 |
| ISIN Number | US25056L1035 |
| Employer ID | 82-3929248 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pratik Shah Ph.D. | Co-Founder, President, Chief Executive Officer, Principal Financial Officer and Executive Chairperson |
| Dr. Sean Jeffries Ph.D. | Chief Operating Officer |
| Dr. Aseem Z. Ansari Ph.D. | Co-Founder and Scientific Advisor |
| Julie D. Burgess CPA | Chief Accounting Officer |
| Doane Chilcoat Ph.D. | Chief Technology Officer |
| Mustapha Parekh | General Counsel |
| Dr. Tadimeti S. Rao Ph.D. | Chief Scientific Officer |
| Jim Kerr | Chief of Manufacturing and Product Development |
| Dr. Chengzhi Zhang Ph.D. | Chief Chemist |
| Dr. Chris M. Storgard M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2025 | 8-K | Current Report |
| May 16, 2025 | EFFECT | Notice of Effectiveness |
| May 13, 2025 | UPLOAD | Filing |
| May 7, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 30, 2025 | DEFR14A | Filing |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |